Related Experiment Videos
Implementation and results of a test dose program with taxanes
Jim A Krieger1, Brad L Stanford, Erin E Ballard
1University of New Mexico Health Sciences Center Cancer Research & Treatment Center, Albuquerque 87131, USA.
Cancer Journal (Sudbury, Mass.)
|August 20, 2002
Summary
Implementing a taxane test-dose policy significantly reduced hypersensitivity reaction severity and drug waste in cancer patients. This approach also decreased hospitalizations, improving patient outcomes and reducing healthcare costs.
Area of Science:
- Oncology
- Pharmacology
- Patient Safety
Background:
- Hypersensitivity reactions to taxane chemotherapy can be severe.
- Drug wastage during chemotherapy administration is a significant concern.
- Standard protocols may not adequately mitigate these risks.
Purpose of the Study:
- To evaluate a pilot taxane test-dose policy.
- To determine if this policy reduces hypersensitivity reaction severity.
- To assess the impact on drug wastage and hospitalizations.
Main Methods:
- Analysis of data from 206 cancer patients receiving their first taxane dose.
- Grading hypersensitivity reaction severity (scale 1-4) before and after policy implementation.
- Calculating average drug wastage pre- and post-policy initiation.
Main Results:
- 10.7% of patients experienced hypersensitivity reactions.
- Test-dose administration reduced mean reaction severity from 3.3 to 1.5.
- Significant reductions in drug wastage (approx. $1784 per reacting patient) and hospitalizations were observed.
Conclusions:
- A taxane test-dose policy effectively minimizes hypersensitivity reaction severity.
- The policy leads to substantial reductions in chemotherapy drug waste.
- Implementation of taxane test-dosing improves patient safety and reduces associated healthcare costs.